2016 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015
DateTitle  
12/21/16AveXis to Use Intended Commercial GMP Product in SMA Type 2 Study
– SMA Type 2 study to initiate in Q2 2017 – – Streamlines development of Type 2 clinical data set – – Conference call and webcast December 21, at 4:30 p.m. EST – CHICAGO, Dec. 21, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today reported that, based on emerging data from its intended commercial Good Manufacturing Practice (GMP) developmen... 
 Printer Friendly Version
11/10/16AveXis Reports Third Quarter 2016 Financial and Operating Results
– AVXS-101 demonstrated continued motor function improvement in ongoing study; majority of patients on proposed therapeutic dose achieved key developmental milestones – – Confirmed single-arm design for pivotal study of SMA Type 1 in U.S. – – Conference call of November 1, 2016, was in lieu of Q3 earnings conference call – CHICAGO, Nov. 10, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare an... 
 Printer Friendly Version
11/08/16AveXis to Present at Jefferies 2016 London Healthcare Conference
CHICAGO, Nov. 08, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that Sean Nolan, president and chief executive officer, will present at the Jefferies 2016 London Healthcare Conference at 11:20 a.m. GMT (6:00 a.m. EST), Wednesday, November 16, 2016. A live, listen-only webcast of the presentation will be accessible on the Even... 
 Printer Friendly Version
11/01/16AveXis Announces Single-Arm Design for U.S. Pivotal Study of AVXS-101 in SMA Type 1 Patients
– Company provides update following receipt of FDA minutes from Type B meeting – – Conference call and webcast November 1 at 4:30 p.m. EDT – CHICAGO, Nov. 01, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that the planned pivotal study of AVXS-101 in spinal muscular atrophy (SMA) Type 1 will reflect a single-arm design, using ... 
 Printer Friendly Version
10/31/16AveXis to Report Third Quarter 2016 Financial and Operating Results
Conference call and webcast on November 10 at 4:30 p.m. EST CHICAGO, Oct. 31, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, will announce financial and operating results for third quarter ended September 30, 2016 on Thursday, November 10, 2016 after the close of U.S.-based financial markets. AveXis management will host a conference call and li... 
 Printer Friendly Version
10/10/16AveXis to Host Webcast Update of Data from Ongoing Phase 1 Clinical Trial of AVXS-101 in Spinal Muscular Atrophy Type 1
-- Data, Including Developmental Milestones, as of September 15, 2016 as presented by Jerry Mendell, M.D. at the International Annual Congress of the World Muscle Society -- -- Webcast Today, October 10, 2016 at 8:30 a.m. EDT – CHICAGO, Oct. 10, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, will host a live webcast briefing regarding data as ... 
 Printer Friendly Version
10/08/16AveXis Reports Interim Data from Ongoing Phase 1 Clinical Trial of AVXS-101 in Spinal Muscular Atrophy Type 1 as Presented at the International Annual Congress of the World Muscle Society
-- Majority of patients on the proposed therapeutic dose achieved key developmental milestones including sitting unassisted; two patients walking independently -- -- Conference call and webcast October 10 at 8:30 a.m. EDT -- CHICAGO--(BUSINESS WIRE)--Oct. 8, 2016-- AveXis, Inc. (NASDAQ: AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases,... 
 Printer Friendly Version
09/08/16AveXis Announces Pricing of Public Offering of Common Stock
CHICAGO, Sept. 08, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced the pricing of an underwritten public offering of 4,250,000 shares of its common stock, 3,960,145 shares of which are being offered by AveXis and 289,855 shares of which are being offered by PBM Capital Investments, LLC, an existing stockholder of AveXis, each at a price to the public of $34.50 per share before underwriting discounts and commissions. The net proceeds to AveXis from the offering, after deduct... 
 Printer Friendly Version
09/06/16AveXis Announces Proposed Public Offering of 4,000,000 Shares of Common Stock
CHICAGO, Sept. 06, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced that it intends to offer and sell, subject to market conditions, 3,566,474 shares of its common stock in an underwritten public offering. Additionally, PBM Capital Investments, LLC, an existing stockholder of AveXis, intends to offer and sell 433,526 shares in the proposed offering. AveXis will not receive proceeds from the sale of the shares by the selling stockholder. The offering is subject to market and ... 
 Printer Friendly Version
08/11/16AveXis Reports Second Quarter 2016 Financial and Operating Results and Interim Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1
-- Interim data through July 1 showed no “events” -- -- Continued motor function improvement with 25% of patients in the proposed therapeutic dose group in the normal range -- -- FDA requested Type B Meeting to discuss SMA Type 1 clinical development pathway -- -- Conference call and webcast August 11 at 4:30 p.m. EDT -- CHICAGO, Aug. 11, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare ... 
 Printer Friendly Version
08/02/16AveXis to Report Second Quarter 2016 Financial and Operating Results and Interim Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1
Conference call and webcast on August 11 at 4:30 p.m. EDT CHICAGO, Aug. 02, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, will announce financial and operating results for second quarter ended June 30, 2016 on Thursday, August 11, 2016 after the close of U.S.-based financial markets. AveXis management will host a conference call and live webca... 
 Printer Friendly Version
07/20/16AveXis Receives U.S. FDA Breakthrough Therapy Designation for AVXS-101 Gene Replacement Therapy for Spinal Muscular Atrophy Type 1
CHICAGO, July 20, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc., (Nasdaq:AVXS) a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for AVXS-101, the company’s lead development candidate for the treatment of spinal muscular atrophy (SMA) Type 1 in pediatric patients.   The Breakthrough Therapy Designation i... 
 Printer Friendly Version
07/11/16AveXis Appoints Michael B. Johannesen as Senior Vice President, General Counsel and Chief Compliance Officer
CHICAGO, July 11, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (Nasdaq:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced the appointment of Michael B. Johannesen to the executive management team as Senior Vice President, General Counsel and Chief Compliance Officer. Mr. Johannesen brings to AveXis nearly 20 years of legal experience within the global pharmaceutical, medical device ... 
 Printer Friendly Version
06/06/16AveXis to Present at Goldman Sachs Annual Global Healthcare Conference and Jefferies 2016 Healthcare Conference
CHICAGO, June 06, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that members of the management team will present at two upcoming investor conferences: The Goldman Sachs 37th Annual Global Healthcare Conference at 10:00 a.m. PDT (1:00 p.m. EDT), Wednesday, June 8, 2016 in Rancho Palos Verdes, Calif. The Jefferies ... 
 Printer Friendly Version
05/16/16AveXis Presents Pulmonary Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1
-- Richard Shell, MD, Presented Data as of April 1, 2016 at the American Thoracic Society 2016 Conference -- CHICAGO, May 16, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases, today reported pulmonary results from an interim analysis of data as of April 1, 2016 from the ongoing Phase 1 trial of AVXS-101 for the treatment of spinal muscular a... 
 Printer Friendly Version
05/12/16AveXis Reports First Quarter 2016 Financial and Operating Results
Encouraging interim data for lead clinical program, AVXS-101, for Spinal Muscular Atrophy Type 1 Conference call May 12 at 4:30 p.m. EDT CHICAGO, May 12, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today reported financial results for the first quarter ended March 31, 2016, and provided an update on recent corporate highlights and upcomin... 
 Printer Friendly Version
05/06/16AveXis Reports Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1
-- Jerry Mendell, MD, Presented Data as of April 1, 2016 at the American Society of Gene & Cell Therapy 19th Annual Meeting -- -- Company to Host Webcast Today at 4:30 p.m. Eastern Daylight Time -- CHICAGO, May 06, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases, today presented an interim analysis of data as of April 1, 2016 from the ... 
 Printer Friendly Version
05/05/16AveXis to Report First Quarter 2016 Financial Results on Thursday, May 12
CHICAGO, May 05, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, will announce financial results for the first quarter ended March 31, 2016 on Thursday, May 12, 2016 after the close of U.S.-based financial markets. AveXis management will host a conference call and live webcast to discuss financial results and provide a business update at 4:30 p.m... 
 Printer Friendly Version
04/25/16AveXis to Report Data from Ongoing Phase 1 Clinical Trial of AVXS-101 in Spinal Muscular Atrophy Type 1
-- Jerry Mendell, M.D., to Present Data as of April 1, 2016 at the American Society of Gene & Cell Therapy 19th Annual Meeting -- -- Company to Host Webcast on Friday, May 6, 2016 at 4:30 p.m. Eastern Daylight Time -- CHICAGO, April 25, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced Jerry Mendell, M.D., director of the Ce... 
 Printer Friendly Version
03/16/16AveXis Reports Fourth Quarter and Full Year 2015 Financial and Operating Results
-- Initial public offering raised $98.2 million in net proceeds -- -- Encouraging interim data for lead clinical program, AVXS-101, for Spinal Muscular Atrophy Type 1 – -- Conference call March 16 at 4:30 p.m. EDT -- CHICAGO, March 16, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today reported financial results for the fourth quarter and ... 
 Printer Friendly Version
03/08/16AveXis to Report Full Year and Fourth Quarter 2015 Financial Results on Wednesday, March 16
CHICAGO, March 08, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, will announce financial results for the fourth quarter and full year ended December 31, 2015 on Wednesday, March 16, 2016 after the close of U.S.-based financial markets. AveXis management will host a conference call and live webcast to discuss financial results and provide a busi... 
 Printer Friendly Version
03/07/16AveXis Announces Appointments of Daniel G. Welch, Terrence C. Kearney and Frank Verwiel, M.D. to Board of Directors
CHICAGO, March 07, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (Nasdaq:AVXS), a leading clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced three appointments to its Board of Directors: Daniel G. Welch, Terrence C. Kearney and Frank Verwiel, M.D., who joined the Board of Directors prior to the company’s initial public offering. Mr. Welch is serving as Non-executive Chairman of the Board.   ... 
 Printer Friendly Version
02/10/16AveXis Announces Pricing of Initial Public Offering
CHICAGO, Feb. 10, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (Nasdaq:AVXS), a clinical stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced the pricing of its initial public offering of 4,750,000 shares of common stock at an initial public offering price of $20.00 per share, before underwriting discounts. In addition, AveXis has granted the underwriters a 30-day option to purchase up to an additional 71... 
 Printer Friendly Version
01/04/16AveXis Announces Completed Enrollment of Phase 1 Clinical Trial for AVXS-101 in Spinal Muscular Atrophy Type 1
Chicago, Ill. – January 4, 2016 – AveXis, Inc., a clinical-stage gene therapy company developing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced patient enrollment has completed for the Phase 1 clinical trial of AVXS-101 for the treatment of spinal muscular atrophy (SMA) Type 1.The trial has enrolled a total of 15 patients who met enrollment criteria of diagnosis of SMA Type 1 before six months of age, with two copies of the S... 
 Printer Friendly Version
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet